Insights

Type Clear all

Select all that apply

Topic Clear all

Select all that apply

icons/content-types/article article

As the COVID-19 outbreak continues to spread across the globe, Curia is diligently monitoring the latest developments.  As such, Curia has established a companywide taskforce to assure a coordinated response across our global network, focusing on em...

icons/content-types/article article

Syringes have been a mainstay of drug delivery for decades – but, as with many other aspects of healthcare, they have recently undergone something of a revolution. The growth of biological medications, the ever-increasing focus on safety, and a...

icons/content-types/video webinar

In this free webinar, the featured speaker will explore the key advances and critical hurdles for translating these emerging molecular biology technologies into real-world applications and commercial processes. Topics for discussion will include: a b...

icons/content-types/article article

Xtalks spoke with Dr. Steef Boerrigter, a senior research scientist at Curia and an expert at materials science. He has extensive experience with experimental screening technologies for polymorphs, salts and cocrystals and has developed computationa...

icons/content-types/video webinar

Curia offers more than 240 high-quality, competitively priced APIs and intermediates, including generics, that cover a variety of therapeutic areas. Take a look at our recently filed DMFs.

icons/content-types/video webinar

Oftentimes, the HPAPI sphere places the spotlight on manufacturing due to the containment challenges on large scale however; handling and containment strategies are also relevant in manufacture support roles such as chemical development, analytical...

icons/content-types/video webinar

The objective of this webinar is to address United States Pharmacopeia (USP) and FDA regulatory trends to demonstrate how to integrate various analytical tests into a robust program that addresses product integrity/compatibility throughout the produc...

icons/content-types/video webinar

Drug formulators should consider the physical properties of their products during pharmaceutical drug development. The physical properties of a solid drug substance are highly dependent on the solid form. It is critical to understand the solid form l...

icons/content-types/article article

Parenteral formulations are broadly characterized as sterile solutions, suspensions, emulsions, and powders for reconstitution for injection or infusion; they are administered directly to subjects, entering the systemic circulation and typically prov...

icons/content-types/fact sheet fact sheet

If you’re involved in late drug discovery, API manufacture, drug product formulation, clinical material production, or manufacture of final dosage form, a basic understanding and awareness of solid form issues could save you a great deal of difficu...

icons/content-types/fact sheet fact sheet

The term amorphous is used loosely in the pharmaceutical industry. A strict definition would limit amorphous to those materials which truly have no long range order, only the short range order characteristic of liquids. However, the term is popular...

icons/content-types/fact sheet fact sheet

It is important to have both a clear, science-based understanding of how the amorphous active drug is formed and also a comprehensive characterization of its fundamental properties, such as Tg, water vapor sorption, and relaxation time as a function...